Related Experiment Video
Updated: Feb 21, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Prognostic performance of cardiogenic shock 4 proteins prediction model in infarct-related cardiogenic shock
Danilo Obradovic1, Lisa Schulz2, Goran Loncar3,4
1Department for Internal Medicine and Cardiology, Heart Centre Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstr. 76, Dresden 01307, Germany.
Insights
The cardiogenic shock 4 proteins (CS4P) risk score effectively stratifies mortality risk in acute myocardial infarction patients. It shows superior prognostication for ST-segment elevation myocardial infarction (STEMI) compared to non-STEMI, especially without prior cardiopulmonary resuscitation (CPR).
Area of Science:
- Cardiology
- Biomarker Discovery
- Prognostic Modeling
Background:
- The CS4P risk score demonstrates strong predictive capabilities for cardiogenic shock (CS) across various etiologies.
- Limited data exists on CS4P performance in CS patients with different acute coronary syndrome (ACS) types.
Purpose of the Study:
- To assess the prognostic value of the CS4P risk score in CS patients with ST-segment elevation myocardial infarction (STEMI) versus non-STEMI.
- To evaluate the CS4P score's performance in STEMI patients with and without prior cardiopulmonary resuscitation (CPR).
Main Methods:
- Post-hoc analysis of the CULPRIT-SHOCK trial data.
- Serum CS4P markers measured via ELISA assays.
- Primary outcome: 30-day composite of mortality or renal replacement therapy.
Main Results:
- CS4P score showed better prognostication in STEMI (AUC 0.74) than NSTEMI (AUC 0.69) CS patients.
- Prognostic performance was higher in STEMI patients without prior CPR (AUC 0.78) compared to those with CPR (AUC 0.70).
- Highest CS4P tertile correlated with increased 30-day mortality (HR 1.42).
Conclusions:
- The CS4P score offers acceptable short-term mortality risk stratification for acute myocardial infarction-related CS.
- The CS4P model provides superior prognostication for STEMI patients compared to NSTEMI.
- Prognostic performance is enhanced in STEMI patients without preceding CPR.
Introduction:
The aim of this analysis was to evaluate the prognostic features of the cardiogenic shock 4 proteins (CS4P) biomarker-based risk score in patients with cardiogenic shock (CS), presenting with ST-segment elevation myocardial infarction (STEMI) vs non-ST-segment elevation myocardial infarction (NSTEMI), with and without cardiopulmonary resuscitation (CPR).The CS4P risk score, validated in cohorts of CS patients with both acute coronary syndrome (ACS) and non-ACS aetiologies, showed advanced predictive metrics compared with other contemporary risk prediction scores for CS. However, there is lack of data concerning the prognostic performance of the CS4P score among CS patients with different forms of ACS.
Methods:
The present analysis is a post-hoc analysis of the randomized CULPRIT-SHOCK trial. The primary outcome was a composite of mortality or necessity for renal replacement therapy at 30-day follow-up. Cardiogenic shock 4 proteins markers were determined in serum using ELISA assays.
Results:
Of the 412 patients with CS included in this study, 240 (58.3%) patients had STEMI and 172 (41.7%) patients had NSTEMI. In CS patients presenting with STEMI, CS4P score exhibited better prognostication of the primary outcome compared with patients with NSTEMI [area under the curve (AUC) 0.74, 95% confidence interval (CI) 0.67-0.80 vs AUC 0.69, 95% CI 0.61-0.77; P = .05). Further, CS4P score displayed a higher prognostic performance in STEMI patients who had not undergone CPR prior to enrolment as compared with STEMI patients with preceding CPR (AUC 0.78; 95% CI 0.65-0.84 vs AUC 0.70, 95% CI 0.62-0.79; P < .001). Cardiogenic shock patients in the highest tertile of the CS4P risk score showed higher mortality rates within 30 days compared to those in the lowest tertile (hazard ratio 1.42, 95% CI 1.11-1.82; P = .005).
Conclusion:
The CS4P score provides acceptable short-term mortality risk stratification among patients with CS due to acute myocardial infarction. The CS4P prediction model exhibits superior prognostication among CS patients with STEMI as compared to NSTEMI and in STEMI patients without CPR prior to hospital presentation.
More Related Videos
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

